| Hypoxia and HIF pathway in cancer and the placenta PS Macklin, J McAuliffe, CW Pugh, A Yamamoto Placenta 56, 8-13, 2017 | 116 | 2017 |
| Systemic silencing of Phd2 causes reversible immune regulatory dysfunction A Yamamoto, J Hester, PS Macklin, K Kawai, M Uchiyama, D Biggs, ... The Journal of Clinical Investigation 129 (9), 3640-3656, 2019 | 30 | 2019 |
| Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy J McAuliffe, HF Chan, L Noblecourt, RA Ramirez-Valdez, ... Journal for immunotherapy of cancer 9 (9), 2021 | 14 | 2021 |
| 835 Heterologous prime boost viral vector vaccination provides protection against intracranial syngeneic murine glioblastoma EE Steffke, T Hana, L Latifi, VP Almeida, J McAuliffe, A Wicki, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Heterologous prime-boost viral vector cancer vaccines have protective effects against a syngeneic mouse model of glioblastoma EE Steffke, L Noblecourt, VP Almeida, A Wicki, J McAuliffe, G Kohanbash, ... The Journal of Immunology 210 (1_Supplement), 145.12-145.12, 2023 | | 2023 |
| Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model EE Steffke, J McAuliffe, VP Almeida, A Wicki, L Noblecourt, G Kohanbash, ... Cancer Research 83 (7_Supplement), 682-682, 2023 | | 2023 |
| Chemotherapy synergizes with cancer vaccines and expands stem-like TCF1+ CD8+ T cells L Noblecourt, A Wicki, V Pereira-Almeida, J McAuliffe, E Steffke, S Panetti, ... bioRxiv, 2023.12. 18.572068, 2023 | | 2023 |
| Developing viral vectored vaccines for MAGE-expressing tumours J McAuliffe University of Oxford, 2020 | | 2020 |
Vinnycius Pereira AlmeidaDPhil student in Clinical Medicine (Immunology), University of OxfordVerified email at ndm.ox.ac.uk
